Establishment of a Public-Private Partnership (PPP) to Support Therapy Selection and Testing within RECOVER-TLC

Key facts

Disease
COVID-19
Start & end year
2024
2025
Known Financial Commitments (USD)
$3,255,169
Funder
National Institutes of Health (NIH)
Principal Investigator
ASSOCIATE VICE PRESIDENT Stacey Adam
Research Location
United States of America
Lead Research Institution
FOUNDATION FOR THE NIH
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Not applicable
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

RECOVER-TLC Abstract for FNIH OT Proposal Establishment of a Public Private Partnership (PPP) to Support RECOVER-TLC September 18, 2024 The NIH will collaborate with the FNIH to create a long COVID-19 public-private partnership (PPP) to accelerate the development of therapeutics, consistent with the FNIH's own mission and the Congressional statute by which the FNIH was established to support the NIH in its mission and to advance collaboration with biomedical researchers from universities, industry, nonprofit organizations, and other federal agencies, including the US Food and Drug Administration (FDA). The overarching goal of the FNIH in this new PPP is to support the NIH in designing and implementing a strategic and coordinated cross-sector approach to address the current long COVID challenges and lack of effective therapies. This PPP is now known as RECOVER-TLC, the NIH Researching COVID to Enhance Recovery- Treating Long COVID (RECOVER-TLC).